Company / Shareholders' Equity
Tarsus Pharmaceuticals, Inc. Shareholders' Equity History
FY2018-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Shareholders' Equity
$343.4M
FY2025
5-year range
$166.7M / $343.4M
FY2021-FY2025
Trend
+53.0%
vs FY2024
Sector context
#121 of 213
Health Care
What the data says
At $343M, Tarsus Pharmaceuticals, Inc.'s shareholders' equity ranks #121 of 213 in the Health Care sector. Shareholders' Equity has increased for 3 consecutive years, from $167M in FY2022 to $343M in FY2025.
Based on SEC 10-K filings.
$343M in FY2025 with a 5-year CAGR of +15.7%.
Improved from $197M to $343M over the past 2 years.
Health Care sector context is included.
Shareholders' Equity over time
Growth rates
- 3-Year CAGR
- +27.2%
- 5-Year CAGR
- +15.7%
- 10-Year CAGR
- -
Sector benchmark
#121 of 213 in Health CareTop 57% of 213This company $343.4M Sector average $2.5B
▼
-86.5% below sector average
Key checks
Key Insights
- Tarsus Pharmaceuticals, Inc.'s shareholders' equity has grown for 3 consecutive years.
- 5-year CAGR of +15.7%, indicating consistent growth.
- In FY2025, shareholders' equity increased 53.0% year-over-year.
- Ranks #121 out of 213 companies in the Health Care sector.
Company context
Key Data Points
- Altman Z-Score 0.92 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Shareholders' EquityValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $343.4M | +53.0% |
| FY2024 | $224.5M | +14.0% |
| FY2023 | $197.0M | +18.1% |
| FY2022 | $166.7M | +0.0% |
| FY2021 | $166.7M | +0.5% |
| FY2020 | $166.0M | +2864.0% |
| FY2019 | -$6.0M | -343.5% |
| FY2018 | -$1.4M | - |
As of FY2025 · SEC 10-K · Updated Jun 30, 2026